Of note, a comprehensive MFC-MRD study reported a list of 22 markers aberrantly expressed in AML patients (namely, CD9, CD18, CD25, CD32, CD44, CD47, CD52, CD54, CD59, CD64, CD68, CD86, CD93, CD96, CD97, CD99, CD123, CD200, CD300a/c, CD366, CD371 and CX3CR1), which allowed to finely dissect normal vs. leukemic stem cell (LSC) pools among hematopoietic progenitors, thus providing a highly sensitive and specific tool for MRD monitoring (putatively, able to detect 1 leukemic cell out of >105 normal BM cells) [10]. Here, CLEC12A is linked to acute myeloid leukemia.